In this episode presented by AnaptysBio, Jennifer Smith-Parker speaks to Dr. Joe Murray, professor of medicine, Division of Gastroenterology and Hepatology, Department of Internal Medicine, and Department of Immunology, The Mayo Clinic; Marilyn Gellar, CEO, The Celiac Disease Foundation; and Dr. Paul Lizzul, chief medical officer, AnaptysBio, about the unmet need for effective treatments for celiac disease, the limitations of the gluten-free diet and the development of ANB033, a first-in-class CD122 antagonist designed to modulate IL-2/IL-15 signaling.

Host

Jennifer Smith-Parker, Director of Insights, BioSpace

Guests

Dr. Joe Murray, Professor of Medicine, Division of Gastroenterology and Hepatology, Department of Internal Medicine and Department of Immunology, The Mayo Clinic

Marilyn Geller, CEO, Celiac Disease Foundation

Dr. Paul Lizzul, Chief Medical Officer, AnaptysBio

Disclaimer: The views expressed in this discussion by guests are their own and do not represent those of their organizations.

Beyond the Gluten-Free Diet: A New Era in Celiac Disease Treatment

BioSpace

Beyond the Gluten-Free Diet: A New Era in Celiac Disease Treatment